Skip to main content
. 2014 Sep 11;25(2):187–193. doi: 10.3109/14397595.2014.951144

Figure 1.

Figure 1.

Effect of abatacept on RA. (A) Effects of abatacept treatment on Simplified Disease Activity Index (SDAI) in 31 patients. Data deficit was compensated by the last observation carried forward (LOCF) method (∗P < 0.05 vs. 0 week [baseline]), Wilcoxon signed-rank test. ABT, abatacept. (B) Effects of abatacept treatment on SDAI in 7 bio-switch patients and 24 bio-naïve patients. Data deficit compensated by the LOCF method (∗P < 0.05 vs. 0 week [baseline]), Wilcoxon signed-rank test. The difference between two groups was examined using Mann–Whitney U-test. ABT, abatacept; N.S, not significant. (C) Effects of abatacept and methotrexate combination treatment on SDAI in 23 patients and of abatacept alone in 8 patients. Data deficit was compensated by the LOCF method (∗P < 0.05 vs 0 week [baseline]), Wilcoxon signed-rank test. Difference between two groups was examined using Mann–Whitney U test. ABT, abatacept; N.S, not significant.